オプションチェーンは、Vincerx Pharmaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Vincerx Pharmaの市場センチメントを評価します。.

Vincerx Pharma (OTC:VINC) 株価情報, オプションチェーン

Vincerx Pharma

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.

VINCERX PHARMA INC by Vincerx Pharma, Inc.

Vincerx Pharma Inc

VINchain

Vince Holding Corp

Vinci Partners Investments Ltd. - Class A Common Shares

Vinci Partners Investments Ltd

Vinci SA

VINCO VENTURES INC by Vinco Ventures, Inc.

Vinco Ventures Inc

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported first-quarter 2025 adjusted earnings per share of $2.28, beating the <a href="https://www.benzinga.com/earnings">street view of $2.10</a>.
Quarterly sales of $13.23 billion marginally outpaced the analyst consensus estimate of $13.12 billion.
Quarterly net sales grew 12% (+15% at constant currency), with volume contributing 15 percentage points to growth.
Heart failure drug Entresto <a href="https://www.novartis.com/sites/novartis_com/files/q1-2025-media-release-en.pdf" target="_blank" rel="noreferrer noopener">sales</a> grew 22% at constant currency to $2.26 billion, driven by demand-led growth in China and Japan, with increased penetration in hypertension.
Cosentyx&nbsp;sales jumped 18% at constant currency to $1.53 billion in the quarter. Sales grew mainly in the US, emerging growth markets, and Europe, driven by recent launches and volume growth in core indications.
Sales of the multiple sclerosis drug&nbsp;Kesimpta&nbsp;reached $899 million, up 43% at constant currency. Novartis said sales grew mainly in the US, emerging growth markets, and Europe, driven by recent launches and volume growth in core indications.
Kisqali sales increased 56% cc to $956 million, including +87% growth in the U.S., with strong momentum from the recently launched early breast cancer indication and continued share gains in metastatic breast cancer.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertainties" rel="noreferrer noopener">Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties</a>.
Core operating income was $5.6 billion, up 23% (+27% at constant currency), mainly driven by higher net sales.
Outlook: For fiscal year 2025, Novartis expects Net sales to grow in the high single digits compared to the mid-to-high single digits <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43380284/novartis-q4-earnings-beat-estimates-ceo-dismisses-entresto-patent-expiration-worries" rel="noreferrer noopener">expected earlier</a>.
2025 core operating income is expected to grow in the low double digits, compared to the high single to low double digits forecasted earlier.
"We assume&nbsp;Tasigna,&nbsp;Promacta, and&nbsp;Entresto&nbsp;US generic entry mid-2025 for forecasting purposes," Novartis said in the release.
Reuters cited CEO Vas Narasimhan, who said the company had historically expanded capacity in Europe and other regions to serve the U.S.
&#8220;We now want to ensure that 100% of the demand of our key products in the U.S. is produced in the U.S.,&#8221; Reuters noted, citing Narasimhan in a media call, declining to provide details on volumes.
"Even in this I think complex geopolitical environment, we feel confident we can deliver now this upgraded guidance," Narasimhan <a target="_blank" href="https://www.cnbc.com/2025/04/29/novartis-earning-q1-2025.html" rel="noreferrer noopener">told</a> CNBC's Squawk Box Europe.
Price Action: Novartis stock is up 0.51% at $113.20 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45066980/spotify-grows-subscribers-and-revenue-but-profit-miss-sends-stock-sliding" target="_blank" rel="noreferrer noopener">Spotify Adds 3 Million Subscribers But Profit Miss Sends Stock Sliding</a></li>
</ul>
Image: Shutterstock

Biotech

Earnings

Large Cap

News

Guidance

Health Care

General

Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has announced the launch of a standalone AI app that will compete with the likes of OpenAI&#8217;s ChatGPT, Google&#8217;s Gemini <a href="https://www.benzinga.com/topic/xai">and xAI&#8217;s Grok</a>. 
What To Know: Meta on Tuesday unveiled the Meta AI app built with Llama 4, designed to give users a more personal AI experience. 
&#8220;People around the world use Meta AI daily across WhatsApp, Instagram, Facebook and Messenger. And now, people can choose to experience a personal AI designed around voice conversations with Meta AI inside a standalone app,&#8221; the company said in a blog <a href="https://about.fb.com/news/2025/04/introducing-meta-ai-app-new-way-access-ai-assistant/">post</a>.
The news comes after CEO Mark Zuckerberg said in January that he believes 2025 will be the year in which a &#8220;highly intelligent and personalized AI assistant&#8221; crosses the 1 billion-user mark, CNBC <a href="https://www.cnbc.com/2025/04/29/meta-launches-standalone-ai-app-to-take-on-chatgpt.html">reported</a>. 
&#8220;I expect Meta AI to be that leading AI assistant,&#8221; Zuckerberg said at the start of the year. 
Meta launched its AI chatbot in 2023 before adding Meta AI search functionality across its family of apps in April. Meta AI had around 700 million monthly active users as of January when Meta last reported quarterly results. 
Meta is set to report results for the first quarter after the market close on Wednesday. The company is expected to report earnings of $5.28 per share and revenue of $41.39 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates. Investors will be watching for signs that the company&#8217;s AI investments are gaining traction after Meta announced plans to spend up to $65 billion building out AI infrastructure this year. 
Meta said on Tuesday that its new AI app is designed to get to know the user, personalizing responses in a natural and seamless way. The new voice conversations feature also helps create a personalized experience by delivering a more natural voice experience trained on conversational dialogue.
&#8220;Meta AI uses Llama 4 to help you solve problems, navigate your daily questions, and better understand the world around you. With the ability to search across the web, it can help you get recommendations, deep dive on a topic, and stay connected with your friends and family. Or if you're just looking to play around with it, we provide conversation starters to inspire your searches,&#8221; the company said. 
META Price Action: <a href="http://benzinga.com/quote/meta">Meta shares</a> were up 0.16% at $550.65 at the time of publication Tuesday. The stock is down about 6% year-to-date, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45065712/meta-q1-earnings-on-deck-expert-sees-growth-at-a-reasonable-price">Meta Q1 Earnings On Deck: Expert Sees Growth At A &#8216;Reasonable Price&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/algifs">Algi Febri Sugita</a>/Shutterstock.

Tech

Meta Launches AI App To Compete With ChatGPT, Gemini, Grok

Ecolab Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) shares are trading higher after the company reported&nbsp;a first-quarter&nbsp;sales decline of&nbsp;2%&nbsp;year-on-year (Y/Y) to&nbsp;$3.69 billion,&nbsp;missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45064296/ecolab-delivers-continued-double-digit-eps-growth-reported-diluted-eps-1-41-adjusted-diluted-eps-1" rel="noreferrer noopener">consensus estimate of&nbsp;$3.70 billion</a>.
Organic sales grew&nbsp;3% Y/Y, led by growth in the Institutional &amp; Specialty, Pest Elimination, and Life Sciences segments.
Effective the first quarter, Ecolab reorganized its segment reporting: Global Industrial is now Global Water (including the former Water, Food &amp; Beverage, and Paper segments); Global Institutional &amp; Specialty remains unchanged (with Healthcare moving in); Global Life Sciences became a standalone segment; and Global Pest Elimination remains a standalone segment.
In fixed currency, Global Water sales grew&nbsp;3% Y/Y&nbsp;to&nbsp;$1.80 billion, Global Institutional &amp; Specialty fell 3% Y/Y to&nbsp;$1.41 billion, Global Life Sciences upped 5% Y/Y&nbsp;to&nbsp;$167.0 million&nbsp;and, Global Pest Elimination increased&nbsp;7% Y/Y&nbsp;to&nbsp;$278.1 million.
Adjusted operating income increased&nbsp;8%&nbsp;Y/Y to&nbsp;$589.6 million, with an adjusted operating margin of&nbsp;15.9% vs.&nbsp;14.3% a year ago.
Organic operating margin expanded 190 bps Y/Y to 16.0%, on improved value pricing and productivity.
Adjusted EPS of&nbsp;$1.50 (+12%&nbsp;Y/Y)&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">in line with the consensus estimate</a>.
The company held&nbsp;$1.16 billion&nbsp;in cash and equivalents as of March 31, 2025.
Outlook: Ecolab expects&nbsp;second-quarter&nbsp;adjusted EPS of&nbsp;$1.84-$1.94 (+10% to 15% Y/Y), vs. the&nbsp;$1.91 estimate.
The company reiterated 2025 adjusted EPS at $7.42&nbsp;–&nbsp;$7.62 (+12% to 15%),&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">compared to the&nbsp;$7.49&nbsp;estimate</a>.
The company repurchased around 0.6 million shares during the quarter.
Christophe Beck, Ecolab's chairman and chief executive officer, said, &#8221;We expect to deliver continued 12-15% earnings growth this year, even as we face a very unpredictable operating environment with soft end market demand and rapidly changing international trade policy. We are making proactive and strategically consistent adjustments to our delivery path due to these external conditions.&#8221;
&#8221;We look to continue to outperform our end markets as we work to convert our strong new business wins, which all leverage our One Ecolab growth initiative and our record innovation pipeline.&#8221;
&#8221;To overcome the impact from tariffs, we are leveraging the strength of Ecolab&#8217;s world-class supply chain, our ‘local for local&#8217; production model, and our recently announced trade surcharge.&#8221;
Investors can gain exposure to the stock via&nbsp;VanEck Environmental Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVX#NYSE">EVX</a>) and&nbsp;iShares U.S. Basic Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYM#NYSE">IYM</a>).
Price Action: ECL shares are up 2.3% at $244.51 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/04/44651693/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo: Shutterstock

Equities

Movers

Market Vectors Environmental Services Index Fund

iShares Trust Dow Jones US Basic Materials Sector Index Fund

Ecolab Navigates Soft Demand, Tariffs With Margin Gains, Confirms Full-Year Forecast

JMP Securities analyst Reni Benjamin reiterates Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) with a Market Outperform and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

PRLD

JMP Securities Reiterates Market Outperform on Prelude Therapeutics, Maintains $4 Price Target

Trading Ideas

Live On CNBC Josh Brown Announces Sold Some Pfizer

Late last week, Valero Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) reported <a href="https://www.benzinga.com/news/earnings/25/04/44977776/valero-posts-higher-than-expected-profit-despite-sharp-refining-margin-decline">better-than-declined quarterly profits</a>.
So far this year, the company's stock has underperformed its closest peer, Marathon Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) by around 6%. It also underperformed the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) by about 3%, according to Goldman Sachs.
The Valero Energy Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586f95cd72b34c0001c9b160/neil-mehta">Analyst Neil Mehta</a> upgraded the rating from Sell to Neutral, while raising the price target from $115 to $127.
The Valero Energy Thesis: Many of the headwinds that resulted in the stock's underperformance are now reversing, Mehta said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The analyst stated three reasons for the upgrade:
<ul>
<li>Following consensus revisions, expectations better reflect "the deceleration in refining profitability with VLO 2025 EPS having been negatively revised by ~50% over the last year," he said.</li>
<li>The crude environment seems to be improving and the OPEC had begun adding barrels into the market, Mehta mentioned. "We believe the incremental heavy barrels should support more favorable crude differentials and support margins at Valero," he further wrote.</li>
<li>Although the demand environment in uncertain, the supply side is faced with larger refining closures.</li>
</ul>
"We additionally highlight the company's relatively healthy balance sheet and strong cash flow generation which we believe supports the company's continued commitment to shareholder returns," Mehta said.
Price Action: Shares of Valero Energy had risen by 0.32% to $115.14 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners</a></li>
</ul>
Image: Shutterstock

Analyst Color

Upgrades

Valero Energy Analyst Is No Longer Bearish: Here Are 3 Reasons Why

JMP Securities analyst Patrick Walravens reiterates Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Market Outperform and maintains $270 price target.

PCTY

JMP Securities Reiterates Market Outperform on Paylocity Holding, Maintains $270 Price Target

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Market Outperform and maintains $28 price target.

KURA

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

American International Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) has outperformed the market over the past 5 years by 1.63% on an annualized basis producing an average annual return of 15.93%. Currently, American International Gr has a market capitalization of $48.61 billion. 
Buying $1000 In AIG: If an investor had bought $1000 of AIG stock 5 years ago, it would be worth $2,083.69 today based on a price of $81.93 for AIG at the time of writing.
<h3>American International Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745944218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American International Gr Stock In The Last 5 Years

<a href="https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs">https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs</a>

AMZN

"The team that runs our ultra low cost Amazon Haul store considered the idea of listing import charges on certain products. This was never approved and is not going to happen."- Amazon

JMP Securities analyst Steven DeLaney reiterates Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) with a Market Outperform and maintains $15 price target.

FBRT

JMP Securities Reiterates Market Outperform on Franklin BSP Realty Trust, Maintains $15 Price Target

Truist Securities analyst Michael Ciarmoli maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $205 to $209.

Truist Securities Maintains Buy on Woodward, Raises Price Target to $209

Truist Securities analyst Gregory Miller maintains OneSpaWorld Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) with a Buy and lowers the price target from $22 to $19.

Truist Securities Maintains Buy on OneSpaWorld Hldgs, Lowers Price Target to $19

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $210 to $199.

BIIB

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $199

Zebra Technologies Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) stock gained on Tuesday after it reported financial results for&nbsp;<a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">the </a>first <a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">quarter</a>. Here's what you need to know.
The mobile computing company reported quarterly sales of $1.31 billion, up by 11.3%, beating analyst estimates of $1.29 billion.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" target="_blank" rel="noreferrer noopener">Zebra Tech Q4 Earnings: Revenue Surges 32%, CEO Cites Strong Retail Demand</a>
Zebra reported adjusted earnings of $4.02 per share, exceeding&nbsp;analyst estimates of $3.62.
Zebra's two main business segments also saw substantial growth during the period. The Enterprise Visibility &amp; Mobility segment recorded net sales of $846 million, up 8% from the previous year. The Asset Intelligence &amp; Tracking segment recorded net sales of $462 million, up 17.9% from the previous year.
The consolidated adjusted gross margin increased 150 bps to 49.6%, primarily due to volume leverage and business mix. Adjusted EBITDA margin expanded by 240 bps to 22.3%.
The company said it had $879 million in cash and cash equivalents as of March 29.
CEO Bill Burns said demand trends continued to be positive into the second quarter, and the company left its full-year outlook unchanged, except for the direct cost of tariffs.&nbsp;
Outlook:&nbsp;For the second quarter, Zebra expects sales growth of 4%-7% or $1.25 billion-$1.30 billion versus the&nbsp;$1.28 billion estimate. The company expects adjusted earnings of $3-$3.50 per share <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">versus estimates of</a> $3.52.
The company reiterated fiscal 2025 net sales growth of 3%-7% or $5.13 billion-$5.33 billion versus the $5.37 billion estimate. It expects adjusted earnings of $13.75-$14.75 (<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" rel="noreferrer noopener">prior $14.75-$15.25</a>) per share versus the $15.89 per share estimate.
ZBRA Price Action:&nbsp;Zebra stock is up 6.57% at 259.49 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback" target="_blank" rel="noreferrer noopener">Alibaba Bets Big On AI With New Cloud Tools As Jack Ma Reemerges In Company Comeback</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock

ZBRA

Zebra Stock Rises As Strong Retail Demand, Sales Beat Drive Big Quarter, But Tariffs Cloud Full-Year Outlook

JMP Securities analyst Silvan Tuerkcan reiterates enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform and maintains $18 price target.

ENGN

JMP Securities Reiterates Market Outperform on enGene Holdings, Maintains $18 Price Target

B of A Securities analyst Allen Lutz maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Underperform and raises the price target from $22 to $26.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $26

B of A Securities analyst Jean Ann maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underperform and raises the price target from $49 to $50.

B of A Securities Maintains Underperform on Cheniere Energy Partners, Raises Price Target to $50

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $46 price target.

CDTX

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $46 Price Target

JMP Securities analyst Mitch Germain reiterates Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Market Outperform and maintains $21 price target.

Comments

Vincerx Pharma

Vincerx Pharma (VINC) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル